HEADER VIRAL PROTEIN 23-NOV-20 7B17 TITLE SARS-COV-SPIKE RBD BOUND TO TWO NEUTRALISING NANOBODIES. COMPND MOL_ID: 1; COMPND 2 MOLECULE: SPIKE PROTEIN S1; COMPND 3 CHAIN: A; COMPND 4 ENGINEERED: YES; COMPND 5 MOL_ID: 2; COMPND 6 MOLECULE: SARS-COV-2 NEUTRALIZING BIPARATOPIC NANOBODY VE,NANOBODY E COMPND 7 FROM LAMA GLAMA,SARS-COV-2 NEUTRALIZING BIPARATOPIC NANOBODY VE, COMPND 8 NANOBODY E FROM LAMA GLAMA; COMPND 9 CHAIN: B; COMPND 10 ENGINEERED: YES; COMPND 11 OTHER_DETAILS: NANOBODY V FROM VICUGNA PACOS AND NANOBODY E FROM LAMA COMPND 12 GLAMA CONNECTED WITH A 15 RESIDUE LINKER,NANOBODY V FROM VICUGNA COMPND 13 PACOS AND NANOBODY E FROM LAMA GLAMA CONNECTED WITH A 15 RESIDUE COMPND 14 LINKER, 1-119 NANOBODY FROM ALPACKA, 120-136: LINKER, 137-263: COMPND 15 NANOBODY FROM LLAMA, 264-283: CLONING AND PURIFICATION TAG,NANOBODY V COMPND 16 FROM VICUGNA PACOS AND NANOBODY E FROM LAMA GLAMA CONNECTED WITH A 15 COMPND 17 RESIDUE LINKER,NANOBODY V FROM VICUGNA PACOS AND NANOBODY E FROM LAMA COMPND 18 GLAMA CONNECTED WITH A 15 RESIDUE LINKER, 1-119 NANOBODY FROM COMPND 19 ALPACKA, 120-136: LINKER, 137-263: NANOBODY FROM LLAMA, 264-283: COMPND 20 CLONING AND PURIFICATION TAG SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS SOURCE 3 2; SOURCE 4 ORGANISM_COMMON: 2019-NCOV, SARS-COV-2; SOURCE 5 ORGANISM_TAXID: 2697049; SOURCE 6 GENE: S, 2; SOURCE 7 EXPRESSION_SYSTEM: HOMO SAPIENS; SOURCE 8 EXPRESSION_SYSTEM_TAXID: 9606; SOURCE 9 MOL_ID: 2; SOURCE 10 ORGANISM_SCIENTIFIC: VICUGNA PACOS, LAMA GLAMA; SOURCE 11 ORGANISM_TAXID: 30538, 9844; SOURCE 12 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 13 EXPRESSION_SYSTEM_TAXID: 562 KEYWDS SPIKE GLYCOPROTEIN, SARS-COV-2, NANOBODY, VIRAL PROTEIN EXPDTA ELECTRON MICROSCOPY AUTHOR B.M.HALLBERG,H.DAS REVDAT 7 23-OCT-24 7B17 1 REMARK REVDAT 6 21-DEC-22 7B17 1 JRNL REVDAT 5 02-JUN-21 7B17 1 COMPND SOURCE REVDAT 4 26-MAY-21 7B17 1 TITLE REVDAT 3 28-APR-21 7B17 1 JRNL REVDAT 2 24-FEB-21 7B17 1 JRNL REVDAT 1 10-FEB-21 7B17 0 JRNL AUTH P.A.KOENIG,H.DAS,H.LIU,B.M.KUMMERER,F.N.GOHR,L.M.JENSTER, JRNL AUTH 2 L.D.J.SCHIFFELERS,Y.M.TESFAMARIAM,M.UCHIMA,J.D.WUERTH, JRNL AUTH 3 K.GATTERDAM,N.RUETALO,M.H.CHRISTENSEN,C.I.FANDREY,S.NORMANN, JRNL AUTH 4 J.M.P.TODTMANN,S.PRITZL,L.HANKE,J.BOOS,M.YUAN,X.ZHU, JRNL AUTH 5 J.L.SCHMID-BURGK,H.KATO,M.SCHINDLER,I.A.WILSON,M.GEYER, JRNL AUTH 6 K.U.LUDWIG,B.M.HALLBERG,N.C.WU,F.I.SCHMIDT JRNL TITL STRUCTURE-GUIDED MULTIVALENT NANOBODIES BLOCK SARS-COV-2 JRNL TITL 2 INFECTION AND SUPPRESS MUTATIONAL ESCAPE JRNL REF SCIENCE V. 371 2021 JRNL REFN ESSN 1095-9203 JRNL PMID 33436526 JRNL DOI 10.1126/SCIENCE.ABE6230 REMARK 2 REMARK 2 RESOLUTION. 4.01 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 SOFTWARE PACKAGES : COOT, CRYOSPARC, CRYOSPARC, CRYOSPARC, REMARK 3 CRYOSPARC, PHENIX REMARK 3 RECONSTRUCTION SCHEMA : BACK PROJECTION REMARK 3 REMARK 3 EM MAP-MODEL FITTING AND REFINEMENT REMARK 3 PDB ENTRY : NULL REMARK 3 REFINEMENT SPACE : REAL REMARK 3 REFINEMENT PROTOCOL : FLEXIBLE FIT REMARK 3 REFINEMENT TARGET : NULL REMARK 3 OVERALL ANISOTROPIC B VALUE : NULL REMARK 3 REMARK 3 FITTING PROCEDURE : NULL REMARK 3 REMARK 3 EM IMAGE RECONSTRUCTION STATISTICS REMARK 3 NOMINAL PIXEL SIZE (ANGSTROMS) : NULL REMARK 3 ACTUAL PIXEL SIZE (ANGSTROMS) : NULL REMARK 3 EFFECTIVE RESOLUTION (ANGSTROMS) : 4.010 REMARK 3 NUMBER OF PARTICLES : 92938 REMARK 3 CTF CORRECTION METHOD : PHASE FLIPPING AND AMPLITUDE REMARK 3 CORRECTION REMARK 3 REMARK 3 EM RECONSTRUCTION MAGNIFICATION CALIBRATION: NULL REMARK 3 REMARK 3 OTHER DETAILS: NULL REMARK 4 REMARK 4 7B17 COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBE ON 23-NOV-20. REMARK 100 THE DEPOSITION ID IS D_1292112475. REMARK 245 REMARK 245 EXPERIMENTAL DETAILS REMARK 245 RECONSTRUCTION METHOD : SINGLE PARTICLE REMARK 245 SPECIMEN TYPE : NULL REMARK 245 REMARK 245 ELECTRON MICROSCOPE SAMPLE REMARK 245 SAMPLE TYPE : PARTICLE REMARK 245 PARTICLE TYPE : POINT REMARK 245 NAME OF SAMPLE : STRUCTURE OF SARS-COV-2 SPIKE REMARK 245 RBD IN COMPLEX WITH SARS-COV-2 REMARK 245 NEUTRALIZING BIPARATOPIC REMARK 245 NANOBODY VE; SPIKE GLYCOPROTEIN; REMARK 245 BIPARATOPIC NANOBODY VE REMARK 245 SAMPLE CONCENTRATION (MG ML-1) : NULL REMARK 245 SAMPLE SUPPORT DETAILS : NULL REMARK 245 SAMPLE VITRIFICATION DETAILS : NULL REMARK 245 SAMPLE BUFFER : NULL REMARK 245 PH : 7.40 REMARK 245 SAMPLE DETAILS : DENSITY FROM LOCALISED REMARK 245 RECONSTRUCTION FROM FULL SPIKE - VE DATA. REMARK 245 REMARK 245 DATA ACQUISITION REMARK 245 DATE OF EXPERIMENT : NULL REMARK 245 NUMBER OF MICROGRAPHS-IMAGES : NULL REMARK 245 TEMPERATURE (KELVIN) : NULL REMARK 245 MICROSCOPE MODEL : TFS KRIOS REMARK 245 DETECTOR TYPE : GATAN K3 BIOQUANTUM (6K X REMARK 245 4K) REMARK 245 MINIMUM DEFOCUS (NM) : NULL REMARK 245 MAXIMUM DEFOCUS (NM) : NULL REMARK 245 MINIMUM TILT ANGLE (DEGREES) : NULL REMARK 245 MAXIMUM TILT ANGLE (DEGREES) : NULL REMARK 245 NOMINAL CS : NULL REMARK 245 IMAGING MODE : BRIGHT FIELD REMARK 245 ELECTRON DOSE (ELECTRONS NM**-2) : 4860.00 REMARK 245 ILLUMINATION MODE : FLOOD BEAM REMARK 245 NOMINAL MAGNIFICATION : NULL REMARK 245 CALIBRATED MAGNIFICATION : NULL REMARK 245 SOURCE : FIELD EMISSION GUN REMARK 245 ACCELERATION VOLTAGE (KV) : 300 REMARK 245 IMAGING DETAILS : NULL REMARK 247 REMARK 247 ELECTRON MICROSCOPY REMARK 247 THE COORDINATES IN THIS ENTRY WERE GENERATED FROM ELECTRON REMARK 247 MICROSCOPY DATA. PROTEIN DATA BANK CONVENTIONS REQUIRE REMARK 247 THAT CRYST1 AND SCALE RECORDS BE INCLUDED, BUT THE VALUES REMARK 247 ON THESE RECORDS ARE MEANINGLESS EXCEPT FOR THE CALCULATION REMARK 247 OF THE STRUCTURE FACTORS. REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 3860 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 20180 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -7.0 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 GLY B 122 REMARK 465 GLY B 123 REMARK 465 GLY B 124 REMARK 465 GLY B 125 REMARK 465 SER B 126 REMARK 465 GLY B 127 REMARK 465 GLY B 128 REMARK 465 GLY B 129 REMARK 465 GLY B 130 REMARK 465 SER B 131 REMARK 465 GLY B 132 REMARK 465 GLY B 133 REMARK 465 GLY B 134 REMARK 465 GLY B 135 REMARK 465 SER B 136 REMARK 465 GLY B 250 REMARK 465 GLY B 251 REMARK 465 TYR B 252 REMARK 465 PRO B 253 REMARK 465 TYR B 254 REMARK 465 ASP B 255 REMARK 465 VAL B 256 REMARK 465 PRO B 257 REMARK 465 ASP B 258 REMARK 465 TYR B 259 REMARK 465 ALA B 260 REMARK 465 GLY B 261 REMARK 465 HIS B 262 REMARK 465 HIS B 263 REMARK 465 HIS B 264 REMARK 465 HIS B 265 REMARK 465 HIS B 266 REMARK 465 HIS B 267 REMARK 470 REMARK 470 MISSING ATOM REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 470 I=INSERTION CODE): REMARK 470 M RES CSSEQI ATOMS REMARK 470 LEU A 335 CD1 CD2 REMARK 470 ARG A 346 CD NE CZ NH1 NH2 REMARK 470 LYS A 386 CD CE NZ REMARK 470 LYS A 462 CE NZ REMARK 470 SER A 477 OG REMARK 470 LYS A 528 CG CD CE NZ REMARK 470 GLN B 1 CG CD OE1 NE2 REMARK 470 LYS B 43 CD CE NZ REMARK 470 ASP B 54 CG OD1 OD2 REMARK 470 LYS B 64 CG CD CE NZ REMARK 470 ASP B 72 CG OD1 OD2 REMARK 470 LYS B 83 CD CE NZ REMARK 470 GLU B 85 CG CD OE1 OE2 REMARK 470 GLN B 105 CG CD OE1 NE2 REMARK 470 GLN B 149 CG CD OE1 NE2 REMARK 470 LYS B 211 CE NZ REMARK 470 LYS B 241 CD CE NZ REMARK 470 SER B 249 OG REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 PHE A 377 58.82 -145.52 REMARK 500 ASN A 422 -56.12 -126.91 REMARK 500 VAL B 184 -51.93 -123.79 REMARK 500 REMARK 500 REMARK: NULL REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: EMD-11980 RELATED DB: EMDB REMARK 900 SARS-COV-SPIKE RBD BOUND TO TWO NEUTRALISING NANOBODIES DBREF 7B17 A 334 528 UNP P0DTC2 SPIKE_SARS2 334 528 DBREF 7B17 B 1 111 PDB 7B17 7B17 1 111 DBREF 7B17 B 112 267 PDB 7B17 7B17 112 267 SEQRES 1 A 195 ASN LEU CYS PRO PHE GLY GLU VAL PHE ASN ALA THR ARG SEQRES 2 A 195 PHE ALA SER VAL TYR ALA TRP ASN ARG LYS ARG ILE SER SEQRES 3 A 195 ASN CYS VAL ALA ASP TYR SER VAL LEU TYR ASN SER ALA SEQRES 4 A 195 SER PHE SER THR PHE LYS CYS TYR GLY VAL SER PRO THR SEQRES 5 A 195 LYS LEU ASN ASP LEU CYS PHE THR ASN VAL TYR ALA ASP SEQRES 6 A 195 SER PHE VAL ILE ARG GLY ASP GLU VAL ARG GLN ILE ALA SEQRES 7 A 195 PRO GLY GLN THR GLY LYS ILE ALA ASP TYR ASN TYR LYS SEQRES 8 A 195 LEU PRO ASP ASP PHE THR GLY CYS VAL ILE ALA TRP ASN SEQRES 9 A 195 SER ASN ASN LEU ASP SER LYS VAL GLY GLY ASN TYR ASN SEQRES 10 A 195 TYR LEU TYR ARG LEU PHE ARG LYS SER ASN LEU LYS PRO SEQRES 11 A 195 PHE GLU ARG ASP ILE SER THR GLU ILE TYR GLN ALA GLY SEQRES 12 A 195 SER THR PRO CYS ASN GLY VAL GLU GLY PHE ASN CYS TYR SEQRES 13 A 195 PHE PRO LEU GLN SER TYR GLY PHE GLN PRO THR ASN GLY SEQRES 14 A 195 VAL GLY TYR GLN PRO TYR ARG VAL VAL VAL LEU SER PHE SEQRES 15 A 195 GLU LEU LEU HIS ALA PRO ALA THR VAL CYS GLY PRO LYS SEQRES 1 B 283 GLN VAL GLN LEU VAL GLU THR GLY GLY GLY LEU VAL GLN SEQRES 2 B 283 PRO GLY GLY SER LEU ARG LEU SER CYS ALA ALA SER GLY SEQRES 3 B 283 PHE THR PHE SER SER TYR ALA MET GLY TRP ALA ARG GLN SEQRES 4 B 283 VAL PRO GLY LYS GLY LEU GLU TRP VAL SER TYR ILE TYR SEQRES 5 B 283 SER ASP GLY SER THR GLU TYR GLN ASP SER VAL LYS GLY SEQRES 6 B 283 ARG PHE THR ILE SER ARG ASP ASN ALA LYS SER THR VAL SEQRES 7 B 283 TYR LEU GLN MET ASN SER LEU LYS PRO GLU ASP THR ALA SEQRES 8 B 283 VAL TYR TYR CYS ALA THR GLU GLY SER LEU GLY GLY TRP SEQRES 9 B 283 GLY ARG ASP PHE GLY SER TRP GLY GLN GLY THR GLN VAL SEQRES 10 B 283 THR VAL SER SER GLY GLY GLY GLY SER GLY GLY GLY GLY SEQRES 11 B 283 SER GLY GLY GLY GLY SER GLN VAL GLN LEU VAL GLU THR SEQRES 12 B 283 GLY GLY GLY PHE VAL GLN PRO GLY GLY SER LEU ARG LEU SEQRES 13 B 283 SER CYS ALA ALA SER GLY VAL THR LEU ASP TYR TYR ALA SEQRES 14 B 283 ILE GLY TRP PHE ARG GLN ALA PRO GLY LYS GLU ARG GLU SEQRES 15 B 283 GLY VAL SER CYS ILE GLY SER SER ASP GLY ARG THR TYR SEQRES 16 B 283 TYR SER ASP SER VAL LYS GLY ARG PHE THR ILE SER ARG SEQRES 17 B 283 ASP ASN ALA LYS ASN THR VAL TYR LEU GLN MET ASN SER SEQRES 18 B 283 LEU LYS PRO GLU ASP THR ALA VAL TYR TYR CYS ALA LEU SEQRES 19 B 283 THR VAL GLY THR TYR TYR SER GLY ASN TYR HIS TYR THR SEQRES 20 B 283 CYS SER ASP ASP MET ASP TYR TRP GLY LYS GLY THR GLN SEQRES 21 B 283 VAL THR VAL SER SER GLY GLY TYR PRO TYR ASP VAL PRO SEQRES 22 B 283 ASP TYR ALA GLY HIS HIS HIS HIS HIS HIS HET NAG A 601 14 HETNAM NAG 2-ACETAMIDO-2-DEOXY-BETA-D-GLUCOPYRANOSE HETSYN NAG N-ACETYL-BETA-D-GLUCOSAMINE; 2-ACETAMIDO-2-DEOXY-BETA- HETSYN 2 NAG D-GLUCOSE; 2-ACETAMIDO-2-DEOXY-D-GLUCOSE; 2-ACETAMIDO- HETSYN 3 NAG 2-DEOXY-GLUCOSE; N-ACETYL-D-GLUCOSAMINE FORMUL 3 NAG C8 H15 N O6 HELIX 1 AA1 PRO A 337 ASN A 343 1 7 HELIX 2 AA2 SER A 349 TRP A 353 5 5 HELIX 3 AA3 TYR A 365 ASN A 370 1 6 HELIX 4 AA4 SER A 383 ASP A 389 5 7 HELIX 5 AA5 ASP A 405 ILE A 410 5 6 HELIX 6 AA6 GLY A 416 ASN A 422 1 7 HELIX 7 AA7 SER A 438 SER A 443 1 6 HELIX 8 AA8 GLY A 502 TYR A 505 5 4 HELIX 9 AA9 ASP B 61 LYS B 64 5 4 HELIX 10 AB1 LYS B 83 THR B 87 5 5 HELIX 11 AB2 LYS B 219 THR B 223 5 5 SHEET 1 AA1 5 ASN A 354 ILE A 358 0 SHEET 2 AA1 5 ASN A 394 ARG A 403 -1 O VAL A 395 N ILE A 358 SHEET 3 AA1 5 PRO A 507 GLU A 516 -1 O TYR A 508 N ILE A 402 SHEET 4 AA1 5 GLY A 431 ASN A 437 -1 N ILE A 434 O VAL A 511 SHEET 5 AA1 5 THR A 376 TYR A 380 -1 N TYR A 380 O GLY A 431 SHEET 1 AA2 3 CYS A 361 VAL A 362 0 SHEET 2 AA2 3 VAL A 524 CYS A 525 1 O CYS A 525 N CYS A 361 SHEET 3 AA2 3 CYS A 391 PHE A 392 -1 N PHE A 392 O VAL A 524 SHEET 1 AA3 2 LEU A 452 ARG A 454 0 SHEET 2 AA3 2 LEU A 492 SER A 494 -1 O GLN A 493 N TYR A 453 SHEET 1 AA4 2 TYR A 473 GLN A 474 0 SHEET 2 AA4 2 CYS A 488 TYR A 489 -1 O TYR A 489 N TYR A 473 SHEET 1 AA5 4 GLN B 3 THR B 7 0 SHEET 2 AA5 4 LEU B 18 SER B 25 -1 O ALA B 23 N VAL B 5 SHEET 3 AA5 4 THR B 77 MET B 82 -1 O MET B 82 N LEU B 18 SHEET 4 AA5 4 PHE B 67 ASP B 72 -1 N ASP B 72 O THR B 77 SHEET 1 AA6 6 LEU B 11 VAL B 12 0 SHEET 2 AA6 6 THR B 107 VAL B 111 1 O THR B 110 N VAL B 12 SHEET 3 AA6 6 ALA B 88 THR B 94 -1 N TYR B 90 O THR B 107 SHEET 4 AA6 6 MET B 34 GLN B 39 -1 N GLN B 39 O VAL B 89 SHEET 5 AA6 6 GLU B 46 ILE B 51 -1 O GLU B 46 N ARG B 38 SHEET 6 AA6 6 THR B 57 TYR B 59 -1 O GLU B 58 N TYR B 50 SHEET 1 AA7 4 LEU B 11 VAL B 12 0 SHEET 2 AA7 4 THR B 107 VAL B 111 1 O THR B 110 N VAL B 12 SHEET 3 AA7 4 ALA B 88 THR B 94 -1 N TYR B 90 O THR B 107 SHEET 4 AA7 4 SER B 102 TRP B 103 -1 N SER B 102 O THR B 94 SHEET 1 AA8 4 GLN B 139 THR B 143 0 SHEET 2 AA8 4 LEU B 154 SER B 161 -1 O SER B 157 N THR B 143 SHEET 3 AA8 4 THR B 213 MET B 218 -1 O LEU B 216 N LEU B 156 SHEET 4 AA8 4 PHE B 203 ARG B 207 -1 N THR B 204 O GLN B 217 SHEET 1 AA9 6 GLY B 146 VAL B 148 0 SHEET 2 AA9 6 THR B 243 VAL B 247 1 O THR B 246 N VAL B 148 SHEET 3 AA9 6 ALA B 224 VAL B 232 -1 N TYR B 226 O THR B 243 SHEET 4 AA9 6 TYR B 168 GLN B 175 -1 N GLN B 175 O VAL B 225 SHEET 5 AA9 6 GLU B 182 GLY B 188 -1 O GLU B 182 N ARG B 174 SHEET 6 AA9 6 THR B 193 TYR B 195 -1 O TYR B 194 N CYS B 186 SHEET 1 AB1 2 THR B 234 TYR B 236 0 SHEET 2 AB1 2 ASN B 236C HIS B 236E-1 O ASN B 236C N TYR B 236 SSBOND 1 CYS A 336 CYS A 361 1555 1555 2.03 SSBOND 2 CYS A 379 CYS A 432 1555 1555 2.04 SSBOND 3 CYS A 391 CYS A 525 1555 1555 2.03 SSBOND 4 CYS A 480 CYS A 488 1555 1555 2.03 SSBOND 5 CYS B 22 CYS B 92 1555 1555 2.03 SSBOND 6 CYS B 158 CYS B 228 1555 1555 2.03 SSBOND 7 CYS B 186 CYS B 236H 1555 1555 2.03 LINK ND2 ASN A 343 C1 NAG A 601 1555 1555 1.54 CRYST1 1.000 1.000 1.000 90.00 90.00 90.00 P 1 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 1.000000 0.000000 0.000000 0.00000 SCALE2 0.000000 1.000000 0.000000 0.00000 SCALE3 0.000000 0.000000 1.000000 0.00000